Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia

Hematology Journal

Volumn 5, Issue 1, 2004, Pages 47-54

  Thornton, Patrick D ^a   Gruszka Westwood, Alicja M ^a   Hamoudi, Rifat A ^a,b   Atkinson, Shayne ^a   Kaczmarek, Pawel ^a   Morilla, Ricardo M ^a   Hilditch, Benjamin L ^a   A'Hern, Roger ^a   Matutes, Estella ^a   Catovsky, Daniel ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

CLL; P53; Therapy; TP53

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; NUCLEIC ACID; PREDNISOLONE; PROTEIN P53; VINCRISTINE;

ALLELE; ARTICLE; CANCER SCREENING; CANCER SURVIVAL; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA SEQUENCE; EXON; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; NUCLEIC ACID BASE SUBSTITUTION; PROTEIN ANALYSIS; PROTEIN DEFECT; PROTEIN EXPRESSION;

DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 10744223348     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200325     Document Type: Article

References (39)

1. Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T et al. p53 expression in B-cell chronic lymphocytic leukaemia: a marker of disease progression and poor prognosis. Blood 1998; 91: 4342-4349.
2. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
3. Prokocimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood 1994; 84: 2391-2411.
4. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
5. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996; 10: 1054-1072.
6. Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M et al. IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res 1998; 26: 205-213.
7. Lens D, Dyer MJ, Garcia-Marco JM, De Schouwer PJ, Hamoudi RA, Jones D et al. p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis. Br J Haematol 1997; 99: 848-857.
8. Wattel E, Preudhomme C, Hequet B, Vanrumbeke M, Quesnel B, Dervite I et al. p53 mutations are associated with resistance to chemotherapy and short survival in haematological malignancies. Blood 1994; 84: 3148-3157.
9. Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogues in chronic B-cell leukaemias. Blood 1995; 85: 1580-1589.
10. Piette J, Neel H, Marechal V. MDM2: keeping p53 under control. Oncogene 1997; 15: 1001-1010.
11. Bonsing BA, Corver WE, Vilet MCBGV, Ould PS, Cornelisse CJ, Fleuren GJ. Specificity of seven monoclonal antibodies evaluated with Western blotting, immunohistochemistry confocal laser scanning microscopy and flow cytometry. Cytometry 1997; 28: 11-24.
12. Konikova E, Kusenda J, Babusikova O. Flow cytometry of p53 protein in some haematological malignacies. Neoplasm 1999; 46: 368-376.
13. Lane DP. Exploiting the p53 pathway for cancer diagnosis and therapy. Br J Cancer 1999; 80 (Suppl 1): 1-5.
14. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77: 81-137.
15. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Soc 1958; 53: 457-481.
16. Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972; 34(B): 187-220.
17. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177-1184.
18. Fenaux P, Preudhomme C, Lai JL, Quiquandon I, Jonveaux P, Vanrumbeke M et al. Mutations of the p53 gene in B-cell chronic lymphocytic leukaemia: a report on 39 cases with cytogenetic analysis. Leukaemia 1992; 6: 246-250.
19. Gruszka-Westwood AM. p53 abnormalities in B-cell lymphoproliferative disorders. Hematology 2001; 6: 241-254.
20. Matutes E, Oscier D, Garcia-Marco J, Ellis J, Copplestone A, Gillingham R et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 1996; 92: 382-388.
21. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001; 98: 814-822.
22. Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 2002; 100: 1404-1409.
23. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990; 50: 7717-7722.
24. Frankel RH, Bayona W, Koslow M, Newcomb EW. p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res 1992; 52: 1427-1433.
25. Lens D, De Schouwer PJ, Hamoudi RA, Abdul-Rauf M, Farahat N, Matutes E et al. p53 abnormalities in B-cell prolymphocytic leukemia. Blood 1997; 89: 2015-2023.
26. Hall PA, Ray A, Lemoine NR, Midgley CA, Krausz T, Lane DP. p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet 1991; 338: 513.
27. Lepelley P, Preudhomme C, Vanrumbeke M, Quesnel B, Cosson A, Fenaux P. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia 1994; 8: 1342-1349.
28. Lehman TA, Bennett WP, Metcalf RA, Welsh JA, Ecker J, Modali RV et al. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 1991; 51: 4090-4096.
29. Nakai H, Misawa S, Toguchida J, Yandell DW, Ishizaki K. Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. Cancer Res 1992; 52: 6588-6593.
30. Gruszka-Westwood AM, Hamoudi RA, Matutes E, Tuset E, Catovsky D. p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood 2001; 97: 3552-3558.
31. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor supressor DNA complex: understanding tumorigenesis mutations. Science 1994; 265: 346-355.
32. Newcomb EW. p53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leukaemia Lymphoma 1995; 17: 211-221.
33. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393: 229-234.
34. Preudhomme C, Fenaux P. The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies. Bri J Haematol 1997; 98: 502-511.
35. French JE, Lacks GD, Trempus C, Dunnick JK, Foley J, Mahler J et al. Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen- and tissue-dependent. Carcinogenesis 2001; 22: 99-106.
36. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Nat Acad Sci 1991; 88: 5413-5417.
37. Barnabas N, Shurafa M, Van Dyke DL, Wolman SR, Clark D, Worsham MJ. Significance of p53 mutations in patients with chronic lymphocytic leukemia: a sequential study of 30 patients. Cancer 2001; 91: 285-293.
38. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997; 337: 529-534.
39. Gaidano G, Newcomb EW, Gong JZ, Tassi V, Neri A, Cortelezzi A et al. Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia. Am J Pathol 1994; 144: 1312-1319.